09:47 AM EDT, 08/08/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) on Friday said that the Positron Emission Tomography (PET) tracer used in a joint study with Massachusetts General Hospital (MGH) scientists shows the ability to capture differences across lesions in multiple sclerosis (MS) patients.

Shares of the company were last seen up 6.3% at $37.55 on the Canadian Securities Exchange.

A study by Drs. Pedro Brugarolas and Eric Klawiter of MGH, published in the European Journal of Nuclear Medicine and Molecular Imaging on Tuesday, evaluated the PET tracer in healthy controls and in people with MS, and was found to have "excellent" properties for imaging the human brain and, "critically and importantly, was able to detect differences across lesions not visible by conventional MRI."

"The published study shows that the PET tracer is highly promising as a biomarker to detect and monitor lesions in people with MS," said Quantum Biopharma ( QNTM ) Vice-President, Scientific and Clinical Affairs, Andrzej Chruscinski. "The ongoing collaborative study with MGH seeks to further evaluate the imaging agent and its potential to demonstrate the effectiveness of drugs, such as Lucid-21-302 (Lucid-MS) that can protect the myelin sheath in MS."

Quantum BioPharma ( QNTM ) said these findings suggest that the tracer holds "significant promise and potential" as a key biomarker to monitor changes in demyelination in MS, and myelin changes in response to its investigational and potentially breakthrough neuroprotective drug, Lucid-21-302.

Price: 37.55, Change: +2.24, Percent Change: +6.34